Nonmyeloablative reduced-intensity transplantation in multiple myeloma

被引：5

作者：

Anagnastopoulos, A ^{[1
]}

Aleman, A ^{[1
]}

Giralt, S ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 01期

关键词：

D O I：

10.1053/j.seminoncol.2003.10.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Reduced-intensity conditioning (RIC) allogeneic transplants are being performed more frequently in a variety of hematologic malignancies. The aim is to exploit the graft-versus-tumor (GVT) effect seen after allografting without the toxicities of myeloablative conditioning. RIC regimens are being extensively explored for salvage therapy of myeloma. Although nonrelapse mortality rates are acceptable, relapse remains the most common cause of treatment failure. New combinations and novel therapies need to be explored to improve outcomes. This strategy should also be employed earlier in the course of the disease. © 2004 Elsevier Inc. All rights reserved.

引用

页码：33 / 36

页数：4

共 38 条

[1]

Albright JW, 2000, J GERONTOL A-BIOL, V55, pB20

[2]

ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484

[3]

Badros A, 2000, BLOOD, V96, p352B

[4] Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation [J].

Bjorkstrand, B ;

Ljungman, P ;

Svensson, H ;

Hermans, J ;

Alegre, A ;

Apperley, J ;

Blade, J ;

Carlson, K ;

Cavo, M ;

Ferrant, A ;

Goldstone, AH ;

deLaurenzi, A ;

Majolino, I ;

Marcus, R ;

Prentice, HG ;

Remes, K ;

Samson, D ;

Sureda, A ;

Verdonck, LF ;

Volin, L ;

Gahrton, G .

BLOOD, 1996, 88 (12) :4711-4718

[5] AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR FIRST REMISSION ACUTE MYELOBLASTIC-LEUKEMIA IN PATIENTS OLDER THAN 50 YEARS - A RETROSPECTIVE ANALYSIS OF THE EUROPEAN-BONE-MARROW-TRANSPLANT-GROUP [J].

CAHN, JY ;

LABOPIN, M ;

MANDELLI, F ;

GOLDSTONE, AH ;

EBERHARDT, K ;

REIFFERS, J ;

FERRANT, A ;

FRANKLIN, I ;

HERVE, P ;

GRATWOHL, A ;

GORIN, NC .

BLOOD, 1995, 85 (02) :575-579

[6]

Champlin R, 1999, ONCOLOGY-NY, V13, P621

[7] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

[8] Distinct categories of immunologic changes in frail elderly [J].

Fahey, JL ;

Schnelle, JF ;

Boscardin, J ;

Thomas, JK ;

Gorre, ME ;

Aziz, N ;

Sadeghi, H ;

Nishanian, P .

MECHANISMS OF AGEING AND DEVELOPMENT, 2000, 115 (1-2) :1-20

[9]

FERRARA JLM, 1991, NEW ENGL J MED, V324, P667

[10] Syngeneic transplantation in multiple myeloma -: a case-matched comparison with autologous and allogeneic transplantation [J].

Gahrton, G ;

Svensson, H ;

Björkstrand, B ;

Apperley, J ;

Carlson, K ;

Cavo, M ;

Ferrant, A ;

Fouillard, L ;

Gratecos, N ;

Gratwohl, A ;

Guilhot, F ;

Deliliers, GL ;

Ljungman, P ;

Masszi, T ;

Milligan, DW ;

Powles, RL ;

Reiffers, J ;

Samson, JD ;

Stoppa, AM ;

Vernant, JP ;

Volin, L ;

Wallvik, J .

BONE MARROW TRANSPLANTATION, 1999, 24 (07) :741-745

← 1 2 3 4 →